Pharmafile Logo

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

With rapid growth comes growing pains…

- PMLiVE

The field of oncology is rapidly growing and evolving. In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). However, with rapid growth comes growing pains.

Specific challenges facing the oncology field

1. Increased competition and evolving standard of care

New competitors are entering the market at a rapid pace, and competition is intensifying. There are currently more than 2,000 oncology products under development. Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017). This competitive intensity tends to focus on smaller patient populations with multiple treatment options.

With a larger number of treatable patients, improving survival rates, more clinical trials, and increased focus on real-world evidence, the definition of ‘standard of care’ is continuously changing. As a result, treatment algorithms are becoming more complex, leading to variable uptake and use of new treatments across regions, clinics, and prescribers.

Further, the time advantage traditionally afforded to new cancer therapies has been substantially reduced due to advances in our understanding of the underlying tumor biology and the emergence of novel treatment modalities. Occasionally, the advantage disappears well before the period of exclusivity ends (2)…

Read the full article here.

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Leveraging Real-Time Health Data for Proactive, Predictive Care

Alex Gilbert, Head of Digital Medicines Development & Life Sciences Partnerships at Huma, explores virtual & decentralized trials, digital biomarkers, digital-first delivery of care, at-home hospitals, and many other thought-provoking...

Top 10 Tips for “Virtualizing” In-person Meetings

While Pharma was already slowly pivoting towards virtual events as a substitute for, or supplement to, in-person meetings, COVID-19 quickly changed virtual events from a nice-to-have to a must. With...

Virtualizing Healthcare with Human-Centric Technology

Dr. Patrick Carroll, Chief Medical Officer at Vida Health, discusses the importance of using a “whole health” approach to chronic disease management, how and why the human connection with a...

Importance of Diversity in Pharma and Clinical Trials

No matter which sector you work in, diversity and inclusion are must-haves!

Case Study: Reducing Travel-Related Emissions and Costs Through Virtual Events

In early 2021, due to COVID-19-related safety concerns and travel and social distancing restrictions, our client needed help to “virtualize” their nationwide, multi-day, multi-business unit internal event with 375 attendees....

Top 10 Reasons Why Virtual Collaboration and Medical Education Will Persist in the New Normal

A version of this article was previously published on Pharmaphorum.There is not a single industry that has been left untouched by COVID-19. While the effects of the pandemic have been devastating...

Data-Driven Approaches for Neurorecovery

Yotam Drechsler (Co-founder/CEO) and Yaron Segal (Co-founder/CINO) from BrainQ Technologies dives into the roles of Brain-Computer Interface technologies and electrophysiology measurements in aiding neurorecovery, the role of AI and machine...

Online Advisory Boards: Top 10 Frequently Asked Questions

It’s hard to imagine a time when some people in the life science industry had never attended a web meeting. Yet, that’s the reality we were living in just two...

Top 10 Tips for Creating Company Culture in a Virtual World

For many companies, the transition from in-office to remote or flexible work at the beginning of the pandemic may have started off a bit rocky. However, a recent survey from LinkedIn...

Democratizing Brain Health with Digital Assessments

Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can...